Aquestive Q3 net loss $11.5M vs $2.0M; revenue up 4% to $13.5M; Anaphylm pre-NDA meeting in Q4

Aquestive Therapeutics, Inc.

2024-Q3 EPS reported -$0.32 revenue$45,694,000

Total revenues $13.5M (+4% YoY); net loss $11.5M ($0.13/sh) vs $2.0M loss in Q3 2023.
Cash $77.9M; FY2024 guidance: revenue $57-60M, adj EBITDA loss $20-23M.
Anaphylm pre-NDA meeting with FDA scheduled Q4 2024; NDA submission targeted Q1 2025, launch Q1 2026 if approved.
AQST-108 (epinephrine topical gel) pre-IND meeting Q4 2024; Phase 2a in alopecia areata planned Q2 2025.
Libervant launched for ages 2-5 with dedicated sales force; commercial and Medicaid coverage expanded nationwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.